Entrar/Registro  
HOME SPANISH
 
Revista de Hematología
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Revista de Hematología >Year 2016, Issue 1


Alvarado-Ibarra M, Cardiel-Silva M, García-Camacho A, González-González L, Hernández-Ruiz E, Leyto-Cruz F, Loera-Fragoso SJ, Martínez-Ramírez M, Martínez-Ríos A, Medina-Coral JE, Ortiz-Zepeda M, Pérez-Zúñiga JM, Ramos-León EM, Romero-Rodelo H, Ron-Guerrero CS, Saavedra-González A, Silva-López S, Silva-Vera K, Tapia-Enríquez AL
Consensus on chronic myelogenous leukemia by hematologists of the ISSSTE
Rev Hematol Mex 2016; 17 (1)

Language: Español
References: 49
Page: 34-62
PDF: 763.34 Kb.


Full text




ABSTRACT

Chronic myeloid leukemia (CML) is a hematological disorder commonly diagnosed in an examination by routine laboratory tests and their care requires referral to a hematologist. Because all hematologists at the Institute for Social Security and Services for State Workers of Mexico (ISSSTE) have therapeutic resources (including tyrosine kinase inhibitors, imatinib, nilotinib and dasatinib) it is important to unify diagnostic, therapeutic approaches and tips for the best care of patients with CML who are treated in hospitals of this institution. For this purpose an expert group of hematologists working in different institutions of the ISSSTE and in different states of the country met in November 2015. With national and international current scientific evidence and the NCCN and ELN current guidelines so far, this consensus applied to insured population of this institution was developed.


Key words: chronic myeloid leukemia, treatment, tyrosine kinase inhibitors.


REFERENCIAS

  1. Granatowicz A, Piatek CI, Moschiano E, et al. An overview and update of chronic myeloid leukemia for primary care phsycians. Korean J Fam Med 2015;36:197-202.

  2. Baccarani M, Pileri S, Steegmann JL, et al. Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol 2012;23:72-77.

  3. NCCN Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia, versión 1.2016. [Actualizado: 2015; citado: diciembre 2015]. Disponible en: www. nccn.org

  4. Chávez-González MA, Ayala-Sánchez M, Mayani H. La leucemia mielode crónica en el siglo XXI: biología y tratamiento. Rev Inv Clin 2009;61:221-232.

  5. Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Nuñez V, et al. Frequencies of the breakpoint cluster región types of the BCR/ ABL fusión gene in Mexican Mestizo patients with chronic myelogenous leukemia. Rev Invest Clin 2004;56:605-608.

  6. López-Hernández MA, Banda-García L, Alvarado-Ibarra M. The treatment of chronic myeloid leukemia: A single-center, 20-year experience. Rev Hematol Mex 2014;15:164-173.

  7. Cervera-Ceballos E, López-Navarro OG, Candelaria M, et al. Epidemiology and outcome of treatment of chronic phase chronic myeloid leukemia (CML) with 400 mg imatinib in Mexico. Rev Hematol Mex 2012;13:50-51.

  8. Aguayo-González A, Tuna-Aguilar EJ. Aspectos actuales de la leucemia mieloide crónica. Rev Invest Clin 2012;64:192- 198.

  9. Ibarra-Hernández A, Sosa-Quintero LS, Garcés-Ruiz OM, et al. Datos epidemiológicos y evaluación de la respuesta al tratamiento en pacientes con leucemia mieloide crónica con inhibidores de tirosina cinasa en el Centro Médico Nacional de Occidente. Memoria del 54ª Congreso de la AMEH. Cartel A1092. Rev Hematol Mex 2013;14:146.

  10. Who´s Certified [base de datos en Internet]. Globocan 2012: Incidencia y mortalidad de todos los cánceres en México. Disponible en: http://globocan.iarc.fr/Pages/ fact_sheets_population.aspx

  11. Ayala M. Estado actual del tratamiento de la leucemia mieloide crónica en México. Rev Hematol Mex 2013;14:5-7.

  12. Limón-Flores JA, Pérez-Lozano U, Solís-Poblano JC, et al. El servicio de hematología del Hospital de Especialidades del IMSS de Puebla. Datos y cifras. Rev Hematol Mex 2014;15:60-68.

  13. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring and management. Am J Hematol 2014;89:547-556.

  14. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of heamatopoietic and lymphoid tissues. Lyon: IARC, 2008.

  15. López-Garrido P, Puerta-Puerta JM, Portero-Frías MA. Guía andaluza de leucemia mieloide crónica. Disponible en: www.sehh.es/images/stories/recursos/2013/documentos/ guias/GUIA-ANDALUZA-LMC.pdf

  16. Ruiz-Argüelles GJ, López-Martínez B, Ramírez-Cabrera JM, et al. Molecular monitoring of the treatment of patients with BCR/ABL (+) chronic myelogenous leukemia. Rev Invest Clin 2001;53:235-239.

  17. Radivoyevitch T, Jankovic GM, Tiu RV, et al. Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys 2014;53:55-63.

  18. Brunner AM, Campigotto F, Sadr-Zadeh H, et al. Trends in all-cause mortality among patients with chronic myeloid leukemia. Cancer 2013;119:2620-2629.

  19. Hughes T, White D. Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. American Society of Hematology (ASH), 2013. Disponible en: http:// asheducationbook.hematologylibrary.org/

  20. Novoa-Gregorio JE, Teixeira-Fernández R. Inhibidores de la tirosina cinasa en el tratamiento de la leucemia mieloide crónica, un cambio en el paradigma. Rev Hematol Mex 2014;15:69-75.

  21. Áviles-Vázquez S, Chávez-González A, Mayani H. Inhibidores de cinasa tirosina (ICT): la nueva revolución en el tratamiento de la leucemia mieloide crónica (LMC). Gaceta Médica de México 2013;149:646-654.

  22. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-884.

  23. Cancer.org [Actualizado: 13 Mar 2015; citado: 16 Dic 2015]. Disponible en: http://www.cancer.org/espanol/ cancer/leucemiamieloidemielogenacronica/guiadetallada/ leucemia-mieloide-mielogena-cronica-treatingtreating- by-phase

  24. Fava C, Rege- Cambrin G, Saglio G. The choice of first-line chronic myelogenous leukemia treatment. Ann Hematol 2015;94:123-131.

  25. Hughes TP, Hochhaus A, Brandorf S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758-3765.

  26. Gugliotta G, Castagnetti F, Breccia M, et al. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica 2015;100:1146-1150.

  27. Hochhaus A, Rosti G, Cross NCP, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia 2015:1-8.

  28. Gafter-Gvili A, Leader A, Gurion R. High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients-systematic review and meta-analysis. Am J Hematology 2011;86:657-662.

  29. López–Arroyo JL, Rico-Ramos HJ, Portillo-García ML. A1203: Respuesta molecular con terapia triple en pacientes con leucemia mielocítica crónica. Memorias del 54 Congreso AMEH. Rev Hematol Mex 2013;14:141.

  30. Best-Aguilera CR, Moreno-Hernández MC, Robles- Rodríguez A, et al. A1035: Respuesta citogenética en leucemia mielocítica crónica tratada con imatinib medida en cualquier momento del tratamiento y su relación con la supervivencia libre de progresión. Memoria del 54 Congreso AMEH. Rev Hematol Mex 2013;14:144.

  31. Arana-Trejo RM, Ignacio-Ibarra G, Saldivar I, et al. A1038: Respuesta citogenética temprana y su correlación con la respuesta molecular en pacientes con leucemia mielocítica crónica tratados con inhibidores de tirosina cinasa. Memoria del 54 Congreso AMEH. Rev Hematol Mex 2013;14:144.

  32. Ayala-Sánchez M, González K, Ávila E, et al. A1135: Monitoreo cardiológico en pacientes con leucemia mielocítica crónica resistentes a imatinib tratados con inhibidores de cinasa de tirosina de segunda generación. Memoria del 54 Congreso AMEH. Rev Hematol Mex 2013;14:148.

  33. Oehler VG. Update on current monitoring recommendations in chronic myeloid leukemia: practical points for clinical practice. Hematology Am Soc Hematol Educ Program 2013;2013:176-183.

  34. Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: The new goal of therapy? Clin Cancer Res 2013;20:310-322.

  35. Baccarani M, Soverini S, De Benedettis C. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor. Am Soc Clin Oncol Educational Book 2014:167-175.

  36. Zhen C, Wang YL. Molecular monitoring of chronic myeloid leukemia. International standardization of BCR-ABL1 quantitation. J Mol Diagn 2013;15:556-564.

  37. García-Gutiérrez V, Puerta JM, Maestro B, et al. Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor? Am J Hematol 2014;89:206-211.

  38. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-2388.

  39. Ursan ID, Jiang R, Pickard EM, et al. Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: A meta-analysis of clinical trials of tirosine kinase inhibitors. J Manag Care Spec Pharm 2015;21:114-122.

  40. Baéz-de la Fuente E, Arellano-Severiano B, Nilotinib en pacientes con leucemia mieloide crónica con falla a imatinib. Rev Med Inst Mex Seguro Soc 2014;52:330-333.

  41. Báez-de la Fuente E, Arellano-Severiano B, Hernández- Valdés R. Eficacia clínica de dasatinib en pacientes con leucemia mielocítica crónica en fase avanzada resistente al imatinib. Memoria del 54 Congreso AMEH. Rev Hematol Mex 2013;14:145.

  42. Ruiz-Argüelles GJ. El efecto de injerto contra tumor en leucemia granulocítica crónica. Rev Invest Clin 2002;54:154- 160.

  43. Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology Am Soc Hematol Educ Program 2010;2010:368-376.

  44. López–Hernández MA, Alvarado-Ibarra M, González- Avante CM. Overall survival of chronic myeloid leukemia patients treated with related donor hematopoietic stem cell transplant or imatinib. Rev Invest Clin 2011;63:494-499.

  45. Zamora-Ortiz G, Vélazquez-Sánchez-De-Cima S, Hernández- Reyes J y col. Veinte años de experiencia con trasplantes de células hematopoyéticas en la Clínica Ruiz de Puebla, México. Rev Hematol Mex 2013;14:63-70.

  46. Gugliotta G, Castagnetti F, Palandri F, et al. Imatinib in chronic myeloid leukemia elderly patients. Aging 2011;3:1125-1126.

  47. Lavi N, Horowitz NA, Brenner B. An update on the management of hematologic malignancies in pregnancy. Womens Health 2014;10:255-266.

  48. Báez-de la Fuente E, Arellano-Severiano B. Embarazo y leucemia mieloide crónica tratada con imatinib. Evolución y monitoreo de una paciente. Rev Med Inst Mex Seguro Soc 2014;52:342-345.

  49. Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood 2012;120:1390-1397.






>Journals >Revista de Hematología >Year 2016, Issue 1
 

· Journal Index 
· Links 






       
Copyright 2019